WO2003073843A3 - Inbred embryonic stem-cell derived mice - Google Patents

Inbred embryonic stem-cell derived mice Download PDF

Info

Publication number
WO2003073843A3
WO2003073843A3 PCT/EP2003/002180 EP0302180W WO03073843A3 WO 2003073843 A3 WO2003073843 A3 WO 2003073843A3 EP 0302180 W EP0302180 W EP 0302180W WO 03073843 A3 WO03073843 A3 WO 03073843A3
Authority
WO
WIPO (PCT)
Prior art keywords
inbred
mice
embryonic stem
cell derived
derived mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/002180
Other languages
French (fr)
Other versions
WO2003073843A2 (en
Inventor
Ralf Kuehn
Anja Rode
Rudolph Jaenisch
Branco Zevnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Artemis Pharmaceuticals GmbH
Original Assignee
Artemis Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artemis Pharmaceuticals GmbH filed Critical Artemis Pharmaceuticals GmbH
Priority to AT03743372T priority Critical patent/ATE306810T1/en
Priority to AU2003210405A priority patent/AU2003210405A1/en
Priority to DE60301953T priority patent/DE60301953T2/en
Priority to EP03743372A priority patent/EP1480515B1/en
Publication of WO2003073843A2 publication Critical patent/WO2003073843A2/en
Publication of WO2003073843A3 publication Critical patent/WO2003073843A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

An improved and reproducible method for the generation of ES mice from inbred ES cells, without the need to generate a chimeric mouse intermediate is provided. The inbred ES cells may be recombinant or genetically modified, resulting in ES mice that are transgenic. The method may also be used for the fast production of ES mice strains homozygous for a defined genetic alteration.
PCT/EP2003/002180 2002-03-05 2003-03-04 Inbred embryonic stem-cell derived mice Ceased WO2003073843A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AT03743372T ATE306810T1 (en) 2002-03-05 2003-03-04 INBREEDED EMBRYONAL STEM CELL-DERIVED MICE
AU2003210405A AU2003210405A1 (en) 2002-03-05 2003-03-04 Inbred embryonic stem-cell derived mice
DE60301953T DE60301953T2 (en) 2002-03-05 2003-03-04 MICE DERIVED FROM INNOVATION MALE DERIVED FROM EMBRYONIC STEM CELLS
EP03743372A EP1480515B1 (en) 2002-03-05 2003-03-04 Inbred embryonic stem-cell derived mice

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36216302P 2002-03-05 2002-03-05
US60/362,163 2002-03-05

Publications (2)

Publication Number Publication Date
WO2003073843A2 WO2003073843A2 (en) 2003-09-12
WO2003073843A3 true WO2003073843A3 (en) 2004-01-22

Family

ID=27789146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/002180 Ceased WO2003073843A2 (en) 2002-03-05 2003-03-04 Inbred embryonic stem-cell derived mice

Country Status (6)

Country Link
US (1) US20030204862A1 (en)
EP (1) EP1480515B1 (en)
AT (1) ATE306810T1 (en)
AU (1) AU2003210405A1 (en)
DE (1) DE60301953T2 (en)
WO (1) WO2003073843A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1802193B1 (en) * 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
WO2007113505A2 (en) 2006-03-30 2007-10-11 The University Court Of The University Of Edinburgh Culture medium containing kinase inhibitors. and uses thereof
GB0615327D0 (en) * 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
WO2007127254A2 (en) * 2006-04-25 2007-11-08 President And Fellows Of Harvard College Compositions and methods for generating transgenic animals
JP5951254B2 (en) * 2008-03-17 2016-07-13 ザ スクリプス リサーチ インスティテュート A combination of chemical and genetic techniques to generate induced pluripotent stem cells
JP2013528062A (en) 2010-06-11 2013-07-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Production of breedable XY female animals from XYES cells
US9732319B2 (en) 2010-12-22 2017-08-15 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
EP2511293A1 (en) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
JP6480926B2 (en) 2013-07-23 2019-03-13 バイオコン・リミテッド Methods for controlling fucosylation levels in proteins
CN120536341A (en) 2014-03-04 2025-08-26 菲特治疗公司 Improved reprogramming methods and cell culture platforms
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
DK3161128T3 (en) 2014-06-26 2018-11-05 Regeneron Pharma METHODS AND COMPOSITIONS FOR TARGETED GENTICAL MODIFICATIONS AND PROCEDURES FOR USE THEREOF
KR102382458B1 (en) 2015-09-17 2022-04-04 리제너론 파마슈티칼스 인코포레이티드 Selection of Pluripotent Cells for Production of Fertility XY Female Mice
CN117737124A (en) 2015-10-16 2024-03-22 菲特治疗公司 Platform for inducing and maintaining ground state pluripotency
EP3403649A1 (en) 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitors and antagonists of gpr84 for the treatment of endometriosis
EP3406253A1 (en) 2017-05-24 2018-11-28 Bayer Aktiengesellschaft Inhibitors and antagonists of human pycr1
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Use of activators and stimulators of sgc comprising a beta2 subunit
US20210230300A1 (en) 2018-06-04 2021-07-29 Bayer Aktiengesellschaft Inhibitors of shp2
KR102398485B1 (en) 2019-02-18 2022-05-16 에이티비 테라퓨틱스 Methods of Production of Binder-Toxin Fusion Proteins in Plant Cells or Whole Plants
US20220249458A1 (en) 2019-04-04 2022-08-11 Bayer Aktiengesellschaft Agonists Of Adiponectin
CN113993534A (en) 2019-04-09 2022-01-28 特殊外科医院 Protein conjugates against iRhom2
WO2021064009A1 (en) 2019-09-30 2021-04-08 Scirhom Gmbh Protein binders to irhom2 epitopes
EP4069301A1 (en) 2019-12-04 2022-10-12 Bayer Aktiengesellschaft Inhibitors of shp2
WO2022038152A1 (en) 2020-08-17 2022-02-24 Atb Therapeutics Recombinant immunotoxin comprising a ribotoxin or rnase
CA3211686A1 (en) 2021-02-26 2022-09-01 Bayer Aktiengesellschaft Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
MX2023010055A (en) 2021-03-01 2023-11-17 Scirhom Gmbh HUMANIZED ANTIBODIES AGAINST IRHOM2.
US20240174744A1 (en) 2021-03-29 2024-05-30 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
US20230190807A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Tcr compounds, compositions, and methods of treating
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
WO2023156634A1 (en) 2022-02-17 2023-08-24 Atb Therapeutics Recombinant immunotoxin comprising a ribosome inactivating protein
WO2024023246A1 (en) 2022-07-28 2024-02-01 Philogen S.P.A. Antibody binding to pd1
CN119998325A (en) 2022-08-08 2025-05-13 Atb治疗公司 Humanized Antibody against CD79b
WO2024161038A1 (en) 2023-02-03 2024-08-08 Immusmol Sas Method of predicting success of a cancer therapy
JP2026520908A (en) 2023-06-05 2026-06-25 ピュア バイオロジクス スプウカ アクツィイナ Anti-GARP antibody and method of use
CN121240857A (en) 2023-06-05 2025-12-30 纯生物制剂股份有限公司 Anti-ROR1 antibody and usage
EP4761754A2 (en) 2023-08-18 2026-06-24 Immatics Biotechnologies GmbH Peptides displayed by mhc for use in immunotherapy against different types of cancer
WO2025180665A1 (en) 2024-02-28 2025-09-04 Evotec International Gmbh Antibodies binding to cd2, and multifunctional molecules comprising such antibodies
WO2025242726A1 (en) 2024-05-21 2025-11-27 Onconick Ltd. Antibody binding to FGFR1 and conjugates comprising the same
CN119699269B (en) * 2024-07-10 2025-10-17 太原市中心医院 Mouse model construction method for psoriasis research based on dihydroxyisobutyrylation modification of SBSN 600-position lysine
WO2026094023A1 (en) 2024-11-04 2026-05-07 Nanodetection Technology, Inc. Recombinant antibody binding to penicillin binding protein 2a (pbp2a)
WO2026098802A1 (en) 2024-11-05 2026-05-15 ETH Zürich Ulk1 inhibitor for the treatment of a neurodegenerative disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015764A2 (en) * 1998-09-11 2000-03-23 University Of Edinburgh Propagation and/or derivation of embryonic stem cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015764A2 (en) * 1998-09-11 2000-03-23 University Of Edinburgh Propagation and/or derivation of embryonic stem cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BURDON T ET AL: "SUPPRESSION OF SHP-2 AND ERK SIGNALLING PROMOTES SELF-RENEWAL OF MOUSE EMBRYONIC STEM CELLS", DEVELOPMENTAL BIOLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 210, 1 June 1999 (1999-06-01), pages 30 - 43, XP000901724, ISSN: 0012-1606 *
EGGAN KEVIN ET AL: "Hybrid vigor, fetal overgrowth, and viability of mice derived by nuclear cloning and tetraploid embryo complementation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 11, 22 May 2001 (2001-05-22), pages 6209 - 6214, XP002206043, ISSN: 0027-8424 *
NAGY A ET AL: "DERIVATION OF COMPLETELY CELL CULTURE-DERIVED MICE FROM EARLY-PASSAGE EMBRYONIC STEM CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 90, September 1993 (1993-09-01), pages 8424 - 8428, XP002938900, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1480515A2 (en) 2004-12-01
DE60301953T2 (en) 2006-07-27
AU2003210405A1 (en) 2003-09-16
WO2003073843A2 (en) 2003-09-12
ATE306810T1 (en) 2005-11-15
US20030204862A1 (en) 2003-10-30
DE60301953D1 (en) 2005-11-24
EP1480515B1 (en) 2005-10-19

Similar Documents

Publication Publication Date Title
AU2003210405A1 (en) Inbred embryonic stem-cell derived mice
AU2002309510A1 (en) Method for modifying plant biomass
WO2003100013A3 (en) NON-REVERTIBLE β-OXIDATION BLOCKED CANDIDA TROPICALIS
WO2003049525A3 (en) Methods and materials for the production of organic products in cells of $i(candida) species
DK0972445T3 (en) Chimeric mouse expressing a human antibody
EP2162537A4 (en) USE OF GENETICALLY MODIFIED ORGANISMS FOR GENERATING BIOMASS DECOMPOSITION ENZYMES
FI950277A0 (en) Production of xenogenic antidotes
WO2002042471A3 (en) Methods and materials for the synthesis of organic products
MX2010002990A (en) Production of isoprenoids.
DK1297172T3 (en) Methods for Generating Modified Glucoproteins
WO2000031237A3 (en) Method of cloning porcine animals
WO2009071334A3 (en) Transposon-mediated mutagenesis in spermatogonial stem cells
EP2150615A4 (en) PROCESS FOR PRODUCING CELLULASE AND HEMICELLULASE HAVING HIGH HYDROLYTIC ACTIVITY
EP1017423A4 (en) Pig cloning using donor cell nuclei from differentiated cells
DE602006007102D1 (en) A TRANSFORMED PLANT EXPRESSING A MUTANEAN CASE AND SYNTHETIZING A MODIFIED THICKNESS
WO2000051424A3 (en) Genetic modification of somatic cells and uses thereof
WO2007140339A8 (en) Production of isoprenoids
JP2009509556A5 (en)
NZ514025A (en) Compositions and methods for the modification of gene transcription
DE60223377D1 (en) MODIFICATION OF MUSHROOMS USING L-ARABINOSE
ATE513049T1 (en) SITE DIRECTED TRANSFORMATION USING AMPLIFICATION VECTORS
WO2002010337A3 (en) Method of cloning porcine animals
ATE414158T1 (en) EXO-ENDO-CELLULASE FUSION PROTEIN
NO20030229D0 (en) A cytochrome P450 enzyme associated with the synthesis of <parta> 12-epoxy groups in the fatty acids of the plants
DK1021552T3 (en) Transgenic Lemnaceae

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003743372

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003743372

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003743372

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP